Infectious Etiology in Inflammatory Bowel Disease – Participation of Mycobacterium avium subsp. paratuberculosis and Adherent-Invasive Strains of Escherichia coli by Freitas, Diogo André Andrade de
 Diogo André Andrade de Freitas 
 
 
 
 
 
 
 
 
 
 
 
Infectious Etiology in Inflammatory Bowel Disease – Participation of Mycobacterium 
avium subsp. paratuberculosis and Adherent-Invasive Strains of Escherichia coli  
 
 
 
 
 
 
 
 
 
 
 
 
1º Ciclo de Ciências da Nutrição 
Faculdade Ciências da Saúde 
Universidade Fernando Pessoa 
Porto, 2019
 
 Diogo André Andrade de Freitas 
 
 
 
 
 
 
 
 
 
 
 
Infectious Etiology in Inflammatory Bowel Disease – Participation of Mycobacterium 
avium subsp. paratuberculosis and Adherent-Invasive Strains of Escherichia coli  
 
 
 
 
 
 
 
 
 
 
 
 
1º Ciclo de Ciências da Nutrição 
Faculdade Ciências da Saúde 
Universidade Fernando Pessoa 
Porto, 2019
 Diogo André Andrade de Freitas 
 
 
 
 
Infectious Etiology in Inflammatory Bowel Disease – Participation of Mycobacterium 
avium subsp. paratuberculosis and Adherent-Invasive Strains of Escherichia coli  
 
 
Declaro para os devidos efeitos ter atuado com integridade na elaboração deste Trabalho 
de Projeto, atesto a originalidade do trabalho, confirmo que não incorri em plágio e que 
todas as frases que retirei de textos de outros autores foram devidamente citadas ou 
redigidas com outras palavras e devidamente referenciadas na bibliografia. 
 
 
__________________________________________________________ 
(Diogo André Andrade de Freitas) 
 
 
Trabalho Complementar apresentado à Universidade 
Fernando Pessoa como parte dos requisitos para obtenção 
do grau de licenciado em Ciências da Nutrição 
 
Orientadora: 
Prof. Doutora Amélia Assunção
 I 
 
 
 
 
 
 
 
 
 
 
 
 
 
Para a Luz da minha vida, para o Nélio e para o Afonso 
 
 
 
 II 
 
Agradecimentos: 
Os meus pais e ao meu irmão por me apoiarem ao longo desta longa caminhada! 
Obrigado! Adoro-vos com todo o meu coração! 
Obrigado aos meus avós, pelo amor incondicional e preocupação! 
Obrigado à Cátia por ser o melhor presente que a faculdade me deu! 
Obrigado à Micaela que depois de tantos anos continua ao meu lado a apoiar-me! 
Muito Obrigado à Doutora Amélia Assunção pela disponibilidade e dedicação ao longo 
do ano e na elaboração deste trabalho. 
Obrigado à Doutora Rita Guerra, pela constante disponibilidade. 
Obrigado a todos os professores por promoverem o meu crescimento pessoal e 
profissional ao longo destes quarto anos. 
    
 
 
 
 
 
 
 
 
A Todos o meu Obrigado!
 III 
 
Index 
 
Abstract………………………………………………………………………………...VI 
Resumo………………………………………………………………………………....VI
I. Introduction………………………………………………………………...……….…1 
II. Methodology…………………………………………………………...……………..2 
II. Inflammatory Bowel Disease………………………………………...…………….....2 
1. Definition and Epidemiology………………………………………………….2 
2. Etiology of Inflammatory Bowel Disease……………………………………3 
i. Genetic Factors……………………………………...…………………3 
ii. Bacterial Triggers………………………………...……………………5 
a. Mycobacterium Avium Paratuberculosis………………..…….....5 
b. Adherent-Invasive Escherichia Coli …………….…………...….8 
iii. Nutrition and Diet…...…………………………………………….…11 
IV. Conclusion…………………………………...……………………………………..12 
V.  References……………………………………...…………………..……………….13 
 
 
 IV 
 
Lista de Abreviaturas: 
AIEC – Adherent-Invasive Escherichia Coli 
CD – Crohn’s Disease 
CEACAM-6 - Carcinoembryonic Antigen Related Cell Adhesion Molecule 6 
DC – Dendritic Cells 
GPR43 - G-Protein-Coupled Receptor 43 
IBD – Inflammatory Bowel Disease 
IEC – Intestinal Epithelial Cells 
IL – Inter-Leucine 
INF-γ – Interferon-Gamma 
MAP – Mycobacterium Avium Paratuberculosis 
NF-kB - Factor Nuclear Kappa B  
NOD2 – Nucleotide-binding oligomerization domain-containing protein 2 
PCR – Polymerase Chain Reaction 
SCFA - Short Chain Fatty Acids 
Th - T Helper Cell 
TNF-α – Tumor Necrosis Factor-Alpha 
UC – Ulcerative Colitis 
  
 V 
 
Infectious Etiology in Inflammatory Bowel Disease – Participation of 
Mycobacterium avium subsp. paratuberculosis and Adherent-Invasive Strains of 
Escherichia coli  
Diogo Freitas1; Amélia Assunção1,2 
1. Estudante finalista do 1º ciclo de Ciências da Nutrição da Universidade Fernando 
Pessoa 
2. Orientadora do trabalho complementar. Docente da Faculdade Ciências da Saúde 
da Universidade Fernando Pessoa 
 
 
 
 
 
 
 
 
Autor para correspondência: 
Diogo André Andrade de Freitas 
Universidade Fernando Pessoa 
Faculdade de Ciências da Saúde  
Rua Carlos da Maia, 296 | 4200 – 150 Porto 
Tel. +351 225074630; E-mail: 28021@ufp.edu.pt 
 
 
  
Short Title: Infectious Etiology in Inflammatory Bowel Disease 
Word Count: 4307 
Number of Tables: 0 
Conflict of Interest: Nothing to Declare 
 VI 
 
Abstract:  
 Inflammatory Bowel Disease (IBD) includes Crohn’s Disease (CD) and 
Ulcerative Colitis (UC), with its etiology still to be established. IBD has been suggested 
to be an interaction between genetic susceptible host, microbiome interactions and 
induction of an abnormal immune response. This study proposes to evaluate the multiple 
literature present and understand the possible activity of bacteria. 
 There have been identified multiple polymorphisms in CD and UC patients, from 
multiple agents related with immune response. These polymorphisms also seem to be 
useful for the colonization of specific bacteria, like Mycobacterium avium. 
Paratuberculosis (MAP) and Adherent-Invasive Escherichia Coli (AIEC) that seem to 
be involved in the IBD etiology as a causative agent or as an opportunist pathogen of the 
genetic susceptibility, however this involvement is still unclear and the studies until now 
are ambiguous when compared with each other.  
 Moreover, environmental factors like diet seem to be involved in the development 
of IBD, especially when considered the high prevalence and increase of IBD in western 
countries and newly westernized countries, respectively. Concluding that a western diet 
is a participant in the development of IBD. On the other side with the presence of plant-
based diet it could be used as a therapeutic agent granting remission in IBD. 
 
 
 
 
Keywords: IBD, Cronh’s Disease, Ulcerative Colitis, Mycobacteirum avium subsp. 
paratuberculosis, Adherent-Invasive Escherichia Coli and Nutrition. 
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Resumo: 
 A Doença Inflamatória Intestinal (DII) inclui a Doença de Crohn(DC) e a Colite 
Ulcerosa(CU), estando a sua etiologia por estabelecer. DII encontra-se associada a uma 
interação entre hospedeiros geneticamente suscetíveis, interações do microbiota e a 
presença de uma resposta inflamatória exacerbada. Com este estudo pretendeu-se avaliar 
a literatura existente e estabelecer uma ligação entre a etiologia e a atividade de agentes 
microbianos.  
 Foram identificados com maior frequência em pacientes com DC e CU, a presença 
um leque variado de polimorfismos, relacionados com os agentes eretores da resposta 
imune. Estes apresentam-se com ferramentas uteis para a colonização de bactérias como 
Mycobacterium avium. Paratuberculosis (MAP) e Adherent-Invasive Escherichia Coli 
(AIEC), que tem sido ligada à etiologia da DII como agentes causadores ou potenciais 
patogénios oportunistas. Contudo, a informação existente é ambígua não permitindo 
concluir a causalidade destes microrganismos. 
 Adicionalmente, a o estudo de fatores ambientais com à dieta apresentam-se 
envolvidos no desenvolvimento da DII, especialmente quando considera a elevada 
prevalência e aumento da DII em “Western Countries” e em “Newly-Westernized 
Countires”, respetivamente. Levando a concluir que uma dieta ocidental é um fator de 
risco para o desenvolvimento da DII, realçando-se assim a dietas de base-vegetal como 
potenciais agentes terapêuticos para a remissão da DII. 
 
 
 
Palavras Chave: IBD, Doença de Cronh, Colite Ulcerosa, Mycobacteirum avium subsp. 
paratuberculosis, Adherent-Invasive Escherichia Coli and Nutrição
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I. Introduction 
 Inflammatory Bowel Disease (IBD) is indeed a group of diseases where the most 
common clinical presentations are Crohn’s Disease (CD) and Ulcerative Colitis (UC)1.  
In UC, inflammation occurs most commonly in the mucosal and submucosal layers of the 
colon, whereas on CD, inflammation tends to be transmural and naturally discontinuous, 
with the capacity to affect any segment of the gastrointestinal tract, most frequently the 
terminal ileum, ascending colon and rectum2,3. There are also pathophysiological 
differences between CD and UC. Indeed. a number of studies refer that the immune 
response in CD is predominantly a Th1 response, mediated by the release of 
proinflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interferon-
gamma (IFN-γ), while in UC a predominance of Th2 response is observed.4 
 IBD was first described during the 20th century5, exhibiting an exponential 
increase in prevalence in the westernized countries (Europe, North America, Australia 
and New Zeeland). Fortunately, in the 21st century its prevalence seems to be stabilized 
in these countries, although is still increasing in the newly westernized countries6. 
 The etiology of both diseases is still debatable. Several studies have pointed out 
that the main cause of IBD is a combination of inherited susceptibility factors, 
environmental factors and altered mucosal immune responses7. These factors would 
allow the establishment of chronic inflammatory responses to microbes in genetical 
susceptible hosts4. Patients with CD tend to show diverse composition of their gut 
microbiota, with the increase in the number of mucosa-associated bacteria and the 
reduction in the overall biodiversity8,9. Specifically, many studies have reported an 
increase in Proteobacteria and Bacteroidetes, and a decrease in Firmicutes, which are 
considered beneficial bacteria.  
 Even though, until now, no single causative microorganism has been confirmed, 
there are two microbial agents that have been intensively investigated: Mycobacterium 
avium subsp. paratuberculosis (MAP) and adherent-invasive strains of Escherichia coli 
(AIEC)9,10. 
 MAP belongs to the genus Mycobacterium and is a member of Mycobacterium 
avium complex. MAP is the causative agent of a chronic granulomatous inflammation of 
the ruminants named Johne’s disease. Since Johne’s disease shows similarities with CD, 
and MAP has been detected in higher frequency in CD patients than in controls10,11, it has 
long been suspected to play a role in CD. On the other hand, AIEC are E. coli variants, 
with ability to adhere, invade intestinal cells (IEC) and replicate within macrophages9. 
Infectious Etiology in Inflammatory Bowel Disease  
2 
 
Their high prevalence in the colonic mucosa of CD and UC patients suggests that AIEC 
may also participate in IBD establishment9. 
  Nutrition has been extensively correlated with IBD, due to the frequent presence 
of multifactorial nutritional deficiencies in IBD patitents4 and to its natural influence with 
microbiota composition. Diet is probably an important etiological factor, since western 
diet was shown to be correlated with the rising of IBD in the western and newly 
westernized countries. It was described that a high-sugar and high-fat diet stimulates the 
growth and metabolic activity of more aggressive commensal bacterial species resulting 
in dysbiosis 4,8,10 with changes in microbiota composition described above.  
 Due to the importance of microbial contribution to IBD onset (either as single 
microorganisms or the whole microbiota community) and the correlation between 
dysbiosis and diet, the objective of this study is to describe the current knowledge about 
MAP and AEIC involvement in IBD and also to investigate the role of nutrition, 
particularly western diet, in IBD establishment. I will also discuss possible nutritional 
interventions to prevent the development and progression of these diseases. 
 
 
II. Methodology 
 This study is a bibliographical review of 51 articles present in the literature, 
recurring to multiple data base like PubMed, Scielo and ScienceDirect. The research for 
the articles was conducted from March to July, and the main key words used were: IBD, 
Crohn’s Disease, Ulcerative Colitis, Mycobacterium Avium Paratuberculosis “MAP”, 
Adherent/Invasive Escherichia Coli “AIEC”, Ethology, Pathology, Nutrition. It was 
defined as exclusion factor any article published from more than 20 years, except articles 
with relevant findings (like Dalziel, 1913).   
 
 
III. Inflammatory Bowel Disease 
1. Definition and Epidemiology 
 IBD encompasses multiple diseases, with CD and UC as the most common 
clinical presentations. Patients who suffer from IBD frequently show fever, abdominal 
pain, diarrhea, rectal bleeding and weight loss12. Signs of malnutrition are also present. 
Perianal disease, abdominal mass and growth failure in children and adolescents are also 
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observed12. Most of the symptoms described are commonly present in CD but less are 
reported in UC12. Both CD and UC have been characterized as relapsing inflammatory 
diseases, since they alternate between relapse and remission phases, being heavily 
associated with the development of intestinal cancer1,13. 
 CD has been characterized by the presence of transmural granulomatous 
inflammation commonly present in the terminal ileum, colon and perianal region being 
cable of affecting any segment of the gastrointestinal tract14,15. CD complications are 
usually presented as intestinal strictures, fistulas and abscesses14.  UC affects the rectum 
and a variable length of the colon, it’s confluent and it involves the mucosa and lamina 
propria, unlike CD that is not as superficial as UC14,16. Histologically, CD presents focal 
patchy chronic inflammation, focal crypt irregularity and non-caseating granulomata 
while UC presents a superficial confluent neutrophilic infiltration with loss of crypt 
architecture, basal plasmacytosis, goblet cell depletion and crypt abscess15,16. CD is 
normally associated with a Th1/Th17 immune response with the secretion of TNF-α, IFN-
γ and IL-17 and UC a Th2 response with a predominant presence of IL-5 and IL-13 
responses with a decrease in IL-331,16. 
 In the last decade the increase in IBD prevalence has been exponential, primarily 
in Western regions like North America and Europe, affecting about 2 million and 1.5 
million of individuals, respectively. Since 1990, IBD prevalence in western countries has 
stabilized or decreased, while newly westernized countries in Africa, Asia and South 
America (for example Brazil) present an increasing prevalence representing a growing 
public health challenge worldwide6.  
 
2. Etiology of IBD 
i. Genetic factors 
 Genetic susceptibility is believed to be one of the main etiological factors of IBD1. 
Genetic variants of multiple genes involved in immune responses have been identified, 
which in association with microbial virulence factors would potentiate bacterial infection 
leading an abnormal immune response1,12. These polymorphisms have been identified in 
higher frequency in CD patients rather than healthy controls, indicating a possible relation 
with CD etiology.  
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 The presence of a defective mucosal barrier and increased intestinal permeability 
has long been observed in CD and UC patients1. The first physical barrier in the gut is 
formed by the mucus layer, produced by polymerization of gel-forming mucins, secreted 
by goblet cells. The mucus layer enables the prevention of bacterial break-through and 
the subsequent intestinal inflammation. CD patients with inflamed ileum have presented 
a reduced expression of MUC1 mRNA as well as MUC3, and MUC5B, reflecting a 
disruption in the mucous layer1,10. The second physical barrier is composed by epithelial 
cells firmly connected by tight junctions maintaining its integrity. Epithelial cells, besides 
its physical barrier capacity, are also responsible for secreting bactericidal agents like 
defensins1. A defective expression of defensins by Paneth cells has been described in CD 
patients.  
 Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an 
intracellular receptor present in epithelial cells as well as in phagocytes and is responsible 
for activating the Factor Nuclear Kappa B (NF-kB) pathway, inducing the autophagy 
pathway, secretion of cytokines and secretion of antimicrobial peptides. The first gene 
variants identified as risk factor for CD were observed in NOD2 gene 1,10.The risk alleles 
present loss-function mutations leading to reduced NF-kB activation, weakened 
inflammatory cytokine response towards muramyl dipeptide (a pathogen-associated 
molecular pattern (PAMP) from gram-positive bacteria), ineffective autophagy and IL-
10 transcription (an anti-inflammatory cytokine)1,10,12. Defective production of 
bactericidal agents like defensins has been related to risk polymorphisms of NOD21. 
Recent Studies showed that NOD2 and Autophagy Related 16 Like 1 (ATG16L1) [the 
latter highly involved in autophagy] gene variants induce altered autophagic process, 
antigen presentation and intracellular bacterial handling in innate response cells like 
macrophages1 and dendritic cells resulting in defective clearance of bacteria. 
 IL-23 is cytokine responsible for the crosswalk between the innate immune 
response and the adaptive immune response 1. The presence of polymorphisms in IL23R 
has been identified in cohorts of CD and UC patients, suggesting that IL-23 might play a 
role in the inflammatory pathway in chronic intestinal inflammation. It has been 
demonstrated that IL-23 is responsible for inducing cytokine secretion in Th17 cells from 
the adaptive immune response1, and so promote inflammation. 
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 CD adaptive immune response has been characterized by an imbalance of effector 
T cells (Th1 and Th17, responsible for releasing high amounts of IFN-, TNF-, IL-17 
and IL-22) and regulatory T cells (Treg, responsible for secretion of anti-inflammatory 
cytokines like IL-10,transforming growth factor[TGB] and IL-5)3. Crucial Loci involved in 
Treg, Th1 and Th17 differentiation may contribute to the immune imbalance present in 
Crohn’s disease3. Additionally, mutations in IL-10R gene derange the highly regulated T 
cell balance and are present in early onset Crohn’s disease3.  
 
ii. Bacterial Triggers 
 The role of microbiome in IBD has been intensively investigated and the concept 
of dysbiosis has been associated with these diseases17. Dysbiosis is an alteration in the 
composition and function of luminal and mucosal-associated bacteria17,18. It has been 
established that that CD and UC patients share common dysbiosis features, consisting in 
a reduced diversity, decrease of beneficial bacteria like Faecalibacterium prausnitzii 
(from Firmicutes family with anti-inflammatory properties) while there has been 
observed an increse in bacteria from Bacteroides and Proteobacteria18,9. From these two 
groups of bacteria there are a lot of possible pathogenic agents (MAP, Clostridium 
difficile, helicobacter species) but also from the altered commensal bacteria (AIEC and 
enterotoxigenic Bacteroides fragilis)10. Drs Sartor et established that the alterations of gut 
microbiota in their composition and metabolic function can contribute to aggressive 
immune responses19. Even though there haven’t been no specific agents identified yet, 
there have two intensively investigated agents: MAP and AIEC10.  
 
a) Mycobacterium avium paratuberculosis 
 Mycobacteria have been correlated to IBD even before CD was first described. It 
was back in 1913 that Kennedy Dolziel5 firstly identified a mycobacteria as a possible 
agent in IBD. MAP belongs to the Mycobacteria genus, along with Mycobacterium 
tuberculosis and Mycobacterium leprae, which are responsible for tuberculosis and 
leprosy, respectively20. MAP is included in the Mycobacterium avium complex (MAC) 
which is comprised by Mycobacterium avium-intercellulare and Mycobacterium avium 
including the subspecies paratuberculosis20,21. MAP is a rod-shaped facultative 
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intracellular, bacterial pathogen, that resists to decolorization with acidic alcohol, just like 
other mycobacteria, that are known to be acid-fast20,22. It is also defined as an obligate 
intracellular pathogen, due to its inability to synthesize mycobactin from environmental 
sources (essential for iron uptake and cell replication)20,22. In human tissues MAP often 
presents as a spheroplast, a cell-wall-deficient state that, differently from other 
mycobacteria, cannot be highlighted by Ziehl-Nielsen staining20. This, the paucibacillary 
infection (with a small number of bacterial units) and the difficulty in establishing MAP 
in vitro cultures from biological samples, are major obstacles in establishing a definitive 
link between MAP and IBD 20,22. 
 MAP is the causative agent of paratuberculosis, also known as Johne’s disease, 
which occurs in beef cattle as well as other mammals including non-human primates, 
causing chronic granulomatous enteritis, reginal lymphangitis and lymphadenitis11,23. Its 
clinical and histological findings show some similarities to CD, partly suggesting an 
association between MAP and IBD22. Infected animals shed the bacilli through milk and 
feces.  Possible routes of human exposure are fecal-oral transmission from the use of 
manure as fertilizer, the consumption of milk and dairies20,22, and the consumption of 
contaminated, treated and untreated water, as well as the use of contaminated water for 
recreational purposes24. Pierce E 24 also states that the consumption of MAP in milk 
represents a higher risk of infections than MAP in water. 
 Since its first association with IBD, and more specifically with CD, the link 
between MAP and CD has become tighter. Since MAP detection is difficult, molecular 
methods have been developed. A specific insertion element (IS900) can be used to detect 
and differentiate DNA MAP from other mycobacteria, via Polymerase chain reaction 
(PCR)20. Another method to identify the presence of MAP in tissues is in situ 
hybridization 20,22. Many studies have demonstrated that the presence of MAP DNA tends 
to be more frequently detected in patients with CD in contrast to healthy controls25,26. 
Such tests have used intestinal biopsies and surgical specimen as well as blood and fecal 
samples22. These results were observed by Pistone et al 27 who found a frequency of 
82.3% CD patients positive for MAP DNA, in biopsies collected from different intestinal 
sites. However, taking into consideration that in the area studied a wide circulation of 
water and other products takes place, it may influence MAP concentrations27. A study by 
Ryan et al 28 where MAP prevalence was evaluated by PCR from bovine intestinal 
granulomas (main area of macrophage-MAP-infected aggregation) obtained by laser 
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capture microdissection, found high prevalence of MAP, leading to the conclusion that 
this technique is efficient and clears some of the previous questions arose. Nazareth et al 
29 also found high MAP DNA frequency in the peripheral blood of IBD patients. Although 
in healthy subjects MAP DNA in also detected 30, MAP may act as an IBD causative 
agent in genetically susceptible subjects. Pierce E11 and Liverani E et al 22 suggests that 
since MAP is a mycobacteria, its pathogenicity could follow a similar pattern as observed 
in other mycobacterial diseases such tuberculosis, where one third of the world is infected 
with M. tuberculosis with but only 5%-10% develop clinical disease. 
 Several studies suggest that MAP infection results in host immunomodulation. In 
2007, Clancy R et al 31 studied the secretion of TNF-α in cultured intestinal tissue biopsies 
of MAP positive (identified via PCR) CD patients using paired antibodies. These patients 
presented higher TNF-α levels in comparison to MAP negative CD patients. These 
findings suggested that in CD a specific defect in NOD2 may affect the handling of MAP 
by macrophages/dendritic cells31. Indeed, MAP was detected in granulomata in CD, 
particularly localized inside macrophages and myofibroblasts31. So, genetic defects that 
contribute to an impaired capacity of innate immune cells for bacterial clearance, results 
in infection establishment31. The high TNF-α secretion found may be explained by this 
impaired macrophage capacity to eliminate MAP 31. However, Clancy R et al 31 discarded 
the possibility that such defect could be related with mutations in NOD2 because 
haplotype mutations were only seen in 30% individuals and TNF-α levels were similar in 
patients with and without NOD2 mutations suggesting that another macrophage defect 
could be related the high TNF-α. These findings, however, are not corroborated by others 
(e.g.  Clancy et al 31) concluding that there is still ambiguity in the understanding of the 
immunomodulatory activity of MAP in CD.  
 Many studies have reported that CD patients positive for MAP DNA, show a 
higher prevalence of Th1 and Th17, as well as their pro-inflammatory cytokines IFN-α 
and IL-1732. MAP-infected macrophages secrete higher levels of pro-inflammatory 
cytokines like IL-23 and IL-12 that in consequence will induce inflammation by 
recruiting inflammatory cells, like Th1 and Th17 causing tissue injury and granuloma 
formation32. The N-glycolyl muramyl dipeptide (MDP) – present in the bacterial wall of 
mycobacteria - and on MAP cell wall, is a natural ligand of NOD2 cytoplasmic receptor33. 
Since MAP persists in macrophages, the continuous NOD2 activation possibly results in 
potent release of pro-inflammatory cytokines, such as TNF- and IL-2333. It is also 
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possible that NOD2 risk polymorphisms are more prone to MAP activation33. IL-23 
induces Th17 to secrete IL-17, promoted by NOD233. The presence of risk variants in IL-
23R and increased IL-23 secretion may induce an expansion of IL-17 production by Th17 
cells leading to an abnormal high presence of this cytokine33. 
 Campos et al 32, also found that MAP infection of macrophages was associated 
with a decreased release of IL-10, an anti-inflammatory cytokine and a deficient secretion 
of TNF-α, going against some of the studies previously mentioned. However, these 
authors hypothesized that even though there was a low secretion of TNF-α from 
infected/colonized macrophages, other cell types secrete TNF-α as a result of the adaptive 
immune response, contributing to the inflammatory response32. TNF- also acts as an 
anti-inflammatory cytokine, being already demonstrated that it can inhibit macrophage 
and dendritic cells from secreting IL-12 and IL-23, which allowed Campos to conclude 
that its low prevalence could implicate in a continuous promotion of inflammatory T cell 
mediated responses32. 
 The immunopathology resulting from MAP infection in IBD is still under 
controversy, with some conflicting results. However, genetic susceptibility is surely a key 
factor for MAP-induced exacerbated inflammatory response of the gut mucosa, 
contributing for IBD establishment6. 
 
b) Adherent-Invasive Strains of Escherichia coli 
 AIEC strains are considered pathobionts, because of their ability to promote 
inflammatory response due to the adaptive evolution of their genome in a specific and 
susceptible host9. These strains have the ability to adhere and invade intestinal epithelial 
cells and macrophages, survive and replicate within the latter, without inducing cell death. 
AIEC strains can translocate across the human intestinal barrier, move to deeper tissues, 
continue activating macrophages and eventually induce the formation of 
granulomata9,34,35.  
Many studies have reported the presence of a higher prevalence of AIEC in IBD 
patients, particularly in CD 29,35. Darfeuille-Michaud A et al 35 observed that AIEC strains 
are deeply associated with the ileal mucosa of CD patients using AIEC detection by PCR 
and DNA in situ hybridization in ileal biopsies. Another study detected a high prevalence 
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of E. Coli DNA in blood samples of CD patients by nested PCR29. Among these, around 
80% carried the fimH30 allele, bearing a mutation strongly associated with AIEC29.  
 
 It is still unclear whether AIEC is a CD causative agent or an aggravating one by 
colonizing the already inflamed mucosa. AIEC presents multiple virulence genes that 
encode for general pathogenic traits like motility, capsule and lipopolysaccharide (LPS) 
expression, serum resistance, iron uptake, adhesion and invasion capacity, biofilm 
formation and the production of long polar fimbriae9. Other virulence genes encode for 
specific traits essential for survival and replication within macrophages, such as stress 
protein HtrA, the thiol-dissulfide oxireductase DsbA, the RNA-binding protein Hfq and 
the FAD-dependent oxyredutcase IbeA, crucial agents in AIEC resistance to phagosome 
acidic pH, oxidative stress, proteolytic enzymes and antimicrobial compounds of 
phagocytes9,36.  
  
 Before adhering to epithelial cells, AIEC need to cross the existing mucous layer 
that protects the epithelial barrier. If a deficiency mucin production (by presence of 
certain polymorphisms) is not present, AIEC can produce a protease, concomitantly by 
the presence of two specific genes in a plasmid-encoded genomic island, arla (related to 
defensin resistance) and arlc, from the OmpT family outer membrane protease 37. These 
genes grant AIEC the ability to alter the secretion of anti-microbial peptides by host 
Paneth cells1,37. 
 Adherence is mediated via the interaction between bacterial type 1 pili, long polar 
fimbriae (LPF) and the host glycoprotein carcinoembryonic antigen related cell adhesion 
molecule 6(CEACAM-6)9,38,39. Type 1 pili express fimH adhesin, that efficiently adheres 
to intestinal epithelial cells39. LPF induce the secretion of pro-inflammatory cytokines 
(IL-8) and chemokines (CCC20) in intestinal epithelial cells, which will lead to 
macrophage and dendritic cell recruitment and further pro-inflammatory cytokine 
secretion of IFN-γ and TNF-α, increased CEACAM-6 expression and amplification of 
AIEC colonization 9,39. CEACAM-6 is abnormally overexpressed in CD patients and its 
expression is positively regulated by adhesion of AIEC and by pro-inflammatory 
cytokines 9,38,39,.  It was already described that once AIEC invades macrophages, 
promotes the secretion of pro-inflammatory cytokines, leading to an amplification loop 
of colonization and inflammation9,38,40.  
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Vimentin, an intermediate filament expressed on cell surfaces, also acts as a 
receptor for AIEC and in addition interacts with NOD2, promoting its recruitment to the 
plasma membrane and facilitating NOD2-dependent antigen detection8,39. However, 
when CD patients bear the NOD2 risk variants interaction with vimentin is inhibited, 
resulting in defective inflammatory response, autophagy induction and a mishandling of 
AIEC in CD9,39.  
AIEC adherence promotes the expression of the pore-forming tight junction 
protein claudin-2 in intestinal epithelial cells (IEC) and induces a reorganization of the 
tight junction from the apical side by displacing zonulae occludens-1 and E-cadherin 
which causes a decrease and loss of barrier function9,38. 
 AIEC invasion, also named internalization, has been described to occur during 
tight junction reorganization 9,38. It occurs by micropinocytosis and vacuolization of 
AIEC into IEC and macrophages38. The outer membrane vesicles of AIEC containing the 
transmembrane protein OmpA are shed and have the ability to interact with the 
endoplasmic reticulum stress response chaperone Gp96 of IEC 41-43. Gp96 is commonly 
overexpressed on apical surface of CD patients IEC 41,43. The interaction of OmpA with 
Gp96 promotes fusion of the outer membrane vesicles with the cell membrane and 
subsequent release of other bacterial components that are involved in actin 
polymerization and microtubule reorganization, inducing AIEC internalization 41-43.In 
association, flagellin binds to the Toll-Like Receptor 5 which induces a IL-8 pro-
inflammatory response, also promoting the internalization into the internal mucosa 44. 
Besides, M cells have the ability to transport foreign antigens and microorganisms to 
organized lymphoid tissue within the mucosa (Peyer’s Patch)38,39; AIEC fimH also binds 
to M cells, by the recognition of glycoprotein 2, allowing the translocation of AIEC from 
the lumen to the mucosa. Cieza et al36 reported that the protein IbeA is associated with 
the invasion of M cells by AIEC, with this study demonstrating in its absence a reduction 
of AIEC invasion. After the internalization, AIEC endosomes will eventually follow a 
maturation process into phagolysomes38. Recent studies have observed that AIEC has the 
capacity to escape autophagy in T84 cells and mouse enterocytes, through the up-
regulation of expression of microRNA (MIR) 30C and MIR130A  levels by the activation 
of the NF-κB pathway, resulting in the decrease expression of Autophagy related 5 
(ATG5) and ATG161 levels (two autophagy proteins), inhibiting autophagy and also 
enhancing inflammatory response31,45,46. These defects have been frequently identified in 
CD leading to the conclusion that AIEC pathogenesis is a combination of host defects 
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and the microbe survival mechanisms39. When AIEC vacuoles fuses with lysosomes 
AIEC resist and take advantage of these harsh conditions, like the acidic pH, through the 
secretion of diverse proteins, as described above32. One of those is IbeA, a protein that is 
a FAD-dependent-oxidoreductase agent, present in AIEC that confers resistance to 
oxidative stress36,39. 
 With the increased TNF-a production induced by AIEC in macrophages, 
inflammation and formation of granulomata takes place in the lymphoid follicles. AIEC 
is able to prevent induction of host cell death by apoptosis, through AIEC-induced 
alteration of caspase-3, leading to its degradation in the proteasome 35,39. Besides 
macrophages and IEC, AIEC is also capable to replicate within neutrophils, however in 
these cells, AIEC induces autophagic death 9,39. 
 Finally, Th17 immune response has been linked with chronic inflammation, being 
characterized as a CD secondary event due to poor bacterial clareance39. However, a 
recent study from Zhang HJ et al 47 observed that IL-17 enhanced expression of 
antimicrobial peptides related to host defense. Using IL-17 knock-out mice, they 
demonstrated that IL-17 maintained colonic epithelial integrity under colonization of 
AIEC47, constituting an important host defense agent, suppressing AIEC-dependent 
exacerbation of experimental colitis. However, other studies also refer that a dysregulated 
expansion of Th17 population, in association with the induction by IL-23, are deleterious 
for the host, due to inflammatory exacerbation48. 
 
iii. Nutrition and Diet 
 Diet plays a dominant role in influencing the composition of the gut microbiota 
and so may influence the pathogenic potential of microorganisms like MAP and AIEC8. 
In a recent study by Roberts et al 49 it was observed that the ingestion of soluble fibers 
reduced E. coli translocation to M cells, whereas the presence of emulsifiers regularly 
present in western diet, showed an increase in the translocation, potentiating E. coli 
colonization of the intestinal mucosa49. This suggested that a western diet may promote 
AIEC pathogenesis while diets rich in fiber may act as a therapeutic agent. In 2010, 
Mitsuto Chiba et al 50 observed a high rate of remission of CD in a group of subjects who 
had a semi-vegetarian diet, comparing to subjects with an omnivore diet 50. Very recently 
a case report by Sandefur K et al 51 disclosed a full remission of CD in a patient on a 
plant-based diet39. Both studies allowed us to understand that there are components on 
these diets that act as anti-inflammatory. Fiber ingestion seem to correlate with an anti-
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inflammatory role. Indeed, Agus A et al 8 described that fiber has the ability to induce the 
production of short chain fatty acids (SCFA), by commensal bacteria8. SCFA have been 
reported to be anti-inflammatory, reducing the production of TNF-α, IL-6 and IFN-γ, 
through the binding with G-protein-coupled receptor 43 (GPR43) present in intestinal 
immune cells8. Mice fed on western-diet regimen (low in fiber and high in sugar and fat), 
showed a lower expression of GPR43, correlating with a failure in  induction of acute 
inflammatory responses responsible for pathogen clearance in an early state, indicating 
that the presence of a western diet could potentiate the overgrowth of AIEC in ileal 
mucosa of CD8. This information comes in agreement with the epidemiology studies 
referring that newly westernized countries as well, showed an increase in the development 
of IBD, leading researchers to conclude that environmental factors like diet have a strong 
impact in such diseases8. These studies present some of the potential effects of western 
diet and show alternative diets associated with IBD remission, reinforcing the importance 
of healthy dietary habits as potential therapeutic agents. 
 
 
IV. Conclusion:  
 Throughout this study it’s was possible to acknowledge the presence of potential 
factors in the development of IBD, that could independently act as causative agents or 
induce the disease via a complex interaction between them. MAP and AIEC, from the 
studies reviewed, there still ambiguity in defining their pathogenicity and possible 
etiology in the disease. Further investigation and development of new producers are 
needed to clearly access their role.  
 Furthermore, studying environmental factors and they’re impact on IBD, is crucial 
for understanding their association with the etiological agent but also for the possible 
capability of preventing and treating this disease.    
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